| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
5ß1 and Caveolin-1, and Activates Src via a Tyrosyl Phosphatase-dependent Pathway in Human Endothelial Cells1
Departments of Pathology and Virology [S. A. W.], Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research [K. A.], and Departments of Pathology and Virology [J. K-O.], Haartman Institute and University of Helsinki, Biomedicum Helsinki and Helsinki University Hospital, FIN-00014 Helsinki, Finland
Endostatin, the COOH-terminal fragment of collagen XVIII, is a potent inhibitor of angiogenesis and tumor growth. To understand the mechanisms behind endostatin action, we analyzed the plasma membrane- extracellular matrix interactions of recombinant human endostatin in cultured microvascular endothelial cells. We observed that endostatin induced rapid clustering of 
5ß1 integrin associated with actin stress fibers and its concomitant colocalization with the membrane anchor protein caveolin-1. Furthermore, endostatin could be coimmunoprecipitated with 5ß1 and caveolin-1 from endothelial cell extracts. Endostatin treatment induced phosphatase-dependent activation of caveolin-associated Src family kinases. The disassembly of actin stress fibers and focal adhesions by endostatin was found to occur via activation of Src and in a tyrosyl phosphatase-dependent manner. The endostatin-treated cells void of the focal adhesions had impaired ability to deposit fibronectin into their extracellular matrices and were unable to migrate in response to basic fibroblast growth factor in a wounding experiment. These results indicate that recombinant endostatin interacts with 5ß1 integrin and caveolin-1 at the endothelial cell surface. In addition, the antimigratory effect of endostatin involves phosphatase-dependent Src activation and impaired cell-matrix interactions.
This article has been cited by other articles:
|
|
 |
|
  A G Richter, S McKeown, S Rathinam, L Harper, P Rajesh, D F McAuley, R Heljasvaara, and D R Thickett Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis Thorax, February 1, 2009; 64(2): 156 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Silva, G. D'Amico, K. M. Hodivala-Dilke, and L. E. Reynolds Integrins: The Keys to Unlocking Angiogenesis Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1703 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Serini, L. Napione, M. Arese, and F. Bussolino Besides adhesion: new perspectives of integrin functions in angiogenesis Cardiovasc Res, May 1, 2008; 78(2): 213 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-Y. Lee, R. M. Tjin Tham Sjin, S. Movahedi, B. Ahmed, E. A. Pravda, K.-M. Lo, S. D. Gillies, J. Folkman, and K. Javaherian Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy Clin. Cancer Res., March 1, 2008; 14(5): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yokoyama, G. Sedgewick, and S. Ramakrishnan Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination Cancer Res., November 15, 2007; 67(22): 10813 - 10822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schaffhauser, T. Veikkola, K. Strittmatter, H. Antoniadis, K. Alitalo, and G. Christofori Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice J. Leukoc. Biol., October 1, 2006; 80(4): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-Q.-N. Nguyen, S. P. Tabruyn, L. Lins, M. Lion, A. M. Cornet, F. Lair, F. Rentier-Delrue, R. Brasseur, J. A. Martial, and I. Struman Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis PNAS, September 26, 2006; 103(39): 14319 - 14324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al. Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., August 1, 2006; 24(22): 3555 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Khan, J. M. Melero-Martin, X. Wu, S. Paruchuri, E. Boscolo, J. B. Mulliken, and J. Bischoff Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin Blood, August 1, 2006; 108(3): 915 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Monaghan-Benson and P. J. McKeown-Longo Urokinase-type Plasminogen Activator Receptor Regulates a Novel Pathway of Fibronectin Matrix Assembly Requiring Src-dependent Transactivation of Epidermal Growth Factor Receptor J. Biol. Chem., April 7, 2006; 281(14): 9450 - 9459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ou-Yang, K.-L. Lan, C.-T. Chen, J.-C. Liu, C.-L. Weng, C.-K. Chou, X. Xie, J.-Y. Hung, Y. Wei, G. N. Hortobagyi, et al. Endostatin-Cytosine Deaminase Fusion Protein Suppresses Tumor Growth by Targeting Neovascular Endothelial Cells Cancer Res., January 1, 2006; 66(1): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mehta and A. B. Malik Signaling Mechanisms Regulating Endothelial Permeability Physiol Rev, January 1, 2006; 86(1): 279 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve Cancer Res., December 1, 2005; 65(23): 11044 - 11050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Baba, Y. Yonemitsu, T. Nakano, M. Onimaru, M. Miyazaki, Y. Ikeda, S. Sumiyoshi, Y. Ueda, M. Hasegawa, I. Yoshino, et al. Cytoplasmic Expression and Extracellular Deposition of an Antiangiogenic Factor, Pigment Epithelium-Derived Factor, in Human Atherosclerotic Plaques Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1938 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nyberg, L. Xie, and R. Kalluri Endogenous Inhibitors of Angiogenesis Cancer Res., May 15, 2005; 65(10): 3967 - 3979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Tjin Tham Sjin, R. Satchi-Fainaro, A. E. Birsner, V.M. S. Ramanujam, J. Folkman, and K. Javaherian A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity Cancer Res., May 1, 2005; 65(9): 3656 - 3663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Short, A. Derrien, R. P. Narsimhan, J. Lawler, D. E. Ingber, and B. R. Zetter Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by {beta}1 integrins J. Cell Biol., February 14, 2005; 168(4): 643 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Zhang, E. G. Teggatz, A.-P. Zou, W. B. Campbell, and P.-L. Li Endostatin uncouples NO and Ca2+ response to bradykinin through enhanced O2-{middle dot} production in the intact coronary endothelium Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H686 - H694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Skovseth, M. J. T. Veuger, D. R. Sorensen, P. M. De Angelis, and G. Haraldsen Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo Blood, February 1, 2005; 105(3): 1044 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. GRANT and R. KALLUR Structural Basis for the Functions of Endogenous Angiogenesis Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 399 - 417. [Abstract] [PDF]
|
|
|
|
|
|
A.-K. Olsson, I. Johansson, H. Akerud, B. Einarsson, R. Christofferson, T. Sasaki, R. Timpl, and L. Claesson-Welsh The Minimal Active Domain of Endostatin Is a Heparin-Binding Motif that Mediates Inhibition of Tumor Vascularization Cancer Res., December 15, 2004; 64(24): 9012 - 9017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. NAVARRO, B. ANAND-APTE, and M.-O. PARAT A role for caveolae in cell migration FASEB J, December 1, 2004; 18(15): 1801 - 1811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Mazzanti, A. Tandle, D. Lorang, N. Costouros, D. Roberts, G. Bevilacqua, and S. K. Libutti Early Genetic Mechanisms Underlying the Inhibitory Effects of Endostatin and Fumagillin on Human Endothelial Cells Genome Res., August 1, 2004; 14(8): 1585 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bix, J. Fu, E. M. Gonzalez, L. Macro, A. Barker, S. Campbell, M. M. Zutter, S. A. Santoro, J. K. Kim, M. Hook, et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through {alpha}2{beta}1 integrin J. Cell Biol., July 5, 2004; 166(1): 97 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Ahn, J.-S. Kim, H.-K. Yu, H.-J. Lee, and Y. Yoon A Truncated Kringle Domain of Human Apolipoprotein(a) Inhibits the Activation of Extracellular Signal-regulated Kinase 1 and 2 through a Tyrosine Phosphatase-dependent Pathway J. Biol. Chem., May 21, 2004; 279(21): 21808 - 21814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wickstrom, K. Alitalo, and J. Keski-Oja An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial Cells J. Biol. Chem., May 7, 2004; 279(19): 20178 - 20185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Citrin, A. K. Lee, T. Scott, M. Sproull, C. Menard, P. J. Tofilon, and K. Camphausen In vivo tumor imaging in mice with near-infrared labeled endostatin Mol. Cancer Ther., April 1, 2004; 3(4): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ricard-Blum, O. Feraud, H. Lortat-Jacob, A. Rencurosi, N. Fukai, F. Dkhissi, D. Vittet, A. Imberty, B. R. Olsen, and M. van der Rest Characterization of Endostatin Binding to Heparin and Heparan Sulfate by Surface Plasmon Resonance and Molecular Modeling: ROLE OF DIVALENT CATIONS J. Biol. Chem., January 23, 2004; 279(4): 2927 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wickstrom, K. Alitalo, and J. Keski-Oja Endostatin Associates with Lipid Rafts and Induces Reorganization of the Actin Cytoskeleton via Down-regulation of RhoA Activity J. Biol. Chem., September 26, 2003; 278(39): 37895 - 37901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sudhakar, H. Sugimoto, C. Yang, J. Lively, M. Zeisberg, and R. Kalluri Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha vbeta 3 and alpha 5beta 1 integrins PNAS, April 15, 2003; 100(8): 4766 - 4771. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
